Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: levofloxacin Clear all
Completed Phase 4 Interventional Results available

Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia

NCT01524302
View directory record Official record
Conditions
Pneumonia, Bacterial, Community-acquired
Interventions
Ceftaroline, Levofloxacin
Drug
Lead sponsor
Gary E. Stein, Pharm.D.
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Sep 17, 2026, 5:22 AM EDT
Completed No phase listed Observational

Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics

NCT00831961
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Conjunctival and nasopharyngeal bacteria cultures
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 17, 2026, 5:22 AM EDT
Withdrawn Phase 1 Interventional

A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery

NCT05441930
View directory record Official record
Conditions
Cataract
Interventions
Levofloxacin Ocular Implant, Control
Drug
Lead sponsor
PolyActiva Pty Ltd
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
St Louis, Missouri • Ladson, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Sep 17, 2026, 5:22 AM EDT
Terminated Phase 4 Interventional Results available

Does Topical Otic Drop Use at Time of Tympanostomy Tube Surgery Improve Outcomes When no Middle Ear Effusion is Present

NCT03655665
View directory record Official record
Conditions
Otitis Media
Interventions
Ofloxacin otic solution
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 10 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 17, 2026, 5:22 AM EDT
Completed No phase listed Observational

Trimethoprim-Sulfamethoxazole vs Levofloxacin as Targeted Therapy for Stenotrophomonas Maltophilia Infections: a Retrospective Cohort Study

NCT04639817
View directory record Official record
Conditions
Stenotrophomonas Infection
Interventions
Levofloxacin, trimethoprim-sulfamethoxazole
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
1,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 17, 2026, 5:22 AM EDT
Completed No phase listed Observational

Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy

NCT00720980
View directory record Official record
Conditions
Granuloma Annulare
Interventions
Not listed
Lead sponsor
Henry Ford Health System
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations

NCT01988779
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
oral levofloxacin, nebulized levofloxacin
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 17, 2026, 5:22 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Pilocarpine After Combined Cataract/Trabectome Surgery

NCT04005079
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Pilocarpine, Ofloxacin, Prednisolone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
30 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Sep 17, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

NCT00250718
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Cancer
Interventions
Vincristine, VP-16, Rituximab, Dexamethasone, Levofloxacin
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 17, 2026, 5:22 AM EDT
Terminated Phase 4 Interventional Results available

Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)

NCT05156437
View directory record Official record
Conditions
Endocarditis
Interventions
Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 17, 2026, 5:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

NCT00042289
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis

NCT00402688
View directory record Official record
Conditions
Prostatitis
Interventions
levofloxacin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
40 Years and older · Male only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
39
States / cities
Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

NCT00703313
View directory record Official record
Conditions
Healthy
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution, 0.3% gatifloxacin ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Sep 17, 2026, 5:22 AM EDT
Terminated Phase 4 Interventional Results available

Early Antibiotics After Aspiration in ICU Patients

NCT05079620
View directory record Official record
Conditions
Aspiration, Aspiration Pneumonia
Interventions
Ceftriaxone, Amoxicillin clavulanic acid, Cefepime, Vancomycin, Levofloxacin
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

NCT02024555
View directory record Official record
Conditions
Sarcoidosis; Antimycobacterial Therapy
Interventions
Levofloxacin, Ethambutol, Azithromycin, Rifampin, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Albany, New York • Cincinnati, Ohio • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Topical Antibiotics in Chronic Rhinosinusitis

NCT03673956
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Mupirocin, Tobramycin, Levofloxacin, Vancomycin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

NCT01978938
View directory record Official record
Conditions
cUTI
Interventions
Eravacycline, Levofloxacin
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
San Diego, California • Torrance, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 17, 2026, 5:22 AM EDT
Terminated Phase 4 Interventional

Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery

NCT00764582
View directory record Official record
Conditions
Corneal Transplantation
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
8
States / cities
Boynton Beach, Florida • Indianapolis, Indiana • Great Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy

NCT00002850
View directory record Official record
Conditions
Infection, Multiple Myeloma
Interventions
ciprofloxacin, ofloxacin, 160 mg trimethoprim and 800 mg sulfamethoxazole
Drug
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
43
States / cities
Mobile, Alabama • Cedar Rapids, Iowa • Ottumwa, Iowa + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 3 Interventional

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

NCT00563433
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
ofloxacin, MSI-78
Drug
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1996
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 4 Interventional

Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis

NCT00645073
View directory record Official record
Conditions
Acute Bacterial Sinusitis
Interventions
cefdinir (Omnicef), levofloxacin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
23
States / cities
Birmingham, Alabama • Columbiana, Alabama • Eclectic, Alabama + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2008 · Synced Sep 17, 2026, 5:22 AM EDT
Completed No phase listed Observational Results available

A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection

NCT00210639
View directory record Official record
Conditions
Musculoskeletal Diseases
Interventions
No intervention
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
6 Months to 16 Years
Enrollment
2,233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
47
States / cities
Hoover, Alabama • Mobile, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

BK Treatment Study

NCT01034176
View directory record Official record
Conditions
BK Viremia
Interventions
levofloxacin, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Worcester, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Sep 17, 2026, 5:22 AM EDT
Completed Phase 4 Interventional

Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs

NCT00392275
View directory record Official record
Conditions
Cataract
Interventions
Ofloxacin 0.3%, Ciprofloxacin 0.3%, Levofloxacin 0.5%, Ofloxacin 400mg, Ciprofloxacin 400mg, Levofloxacin 250mg
Drug
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Sep 17, 2026, 5:22 AM EDT